Israel Englander’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,425,065
| Closed | -$1.18M | – | 6116 |
|
|
2025
Q1 | $1.18M | Sell |
1,425,065
-291,436
| -17% | -$281K | ﹤0.01% | 4236 |
|
|
2024
Q4 | $1.63M | Sell |
1,716,501
-329,302
| -16% | -$311K | ﹤0.01% | 3795 |
|
|
2024
Q3 | $2.05M | Buy |
2,045,803
+187,815
| +10% | +$208K | ﹤0.01% | 3685 |
|
|
2024
Q2 | $2.3M | Buy |
1,857,988
+30,265
| +2% | +$30.8K | ﹤0.01% | 3419 |
|
|
2024
Q1 | $2.38M | Buy |
1,827,723
+979,723
| +116% | +$1.12M | ﹤0.01% | 3575 |
|
|
2023
Q4 | $1.06M | Sell |
848,000
-147,984
| -15% | -$164K | ﹤0.01% | 4112 |
|
|
2023
Q3 | $1.29M | Buy |
995,984
+354,331
| +55% | +$572K | ﹤0.01% | 3978 |
|
|
2023
Q2 | $1.1M | Sell |
641,653
-11,916
| -2% | -$18.9K | ﹤0.01% | 3967 |
|
|
2023
Q1 | $954K | Buy |
653,569
+179,215
| +38% | +$344K | ﹤0.01% | 4136 |
|
|
2022
Q4 | $768K | Buy |
474,354
+192,444
| +68% | +$443K | ﹤0.01% | 4407 |
|
|
2022
Q3 | $944K | Sell |
281,910
-1,245
| -0.4% | -$5.62K | ﹤0.01% | 4390 |
|
|
2022
Q2 | $1.03M | Buy |
283,155
+253,944
| +869% | +$1.15M | ﹤0.01% | 4339 |
|
|
2022
Q1 | $211K | Buy |
+29,211
| New | +$249K | ﹤0.01% | 5797 |
|
|
2021
Q2 | – | Sell |
-25,013
| Closed | -$732K | – | 6812 |
|
|
2021
Q1 | $732K | Sell |
25,013
-31,815
| -56% | -$932K | ﹤0.01% | 4491 |
|
|
2020
Q4 | $1.7M | Buy |
+56,828
| New | +$1.78M | ﹤0.01% | 3372 |
|
Israel Englander's KRON Position: Q2 2025 in Review
Israel Englander sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 1,425,065 shares — an estimated $1.18M sold.
Israel Englander first reported a position in KRON in Q4 2020 and held it in 15 quarters. The position peaked at $2.38M in Q1 2024. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Israel Englander reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Israel Englander sold 1,425,065 Kronos Bio shares in Q2 2025, an estimated $1.18M.
- Israel Englander first reported a position in Kronos Bio in Q4 2020 and held it in 15 quarters.
- Israel Englander's Kronos Bio position peaked at $2.38M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.